Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07533565) titled 'A Pilot Study of Mirabegron and Montelukast in Cirrhotic Patients' on April 10.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Kafrelsheikh University
Condition:
Cirrhosis
Asthma
Intervention:
Drug: Mirabegron 100 mg
Drug: Mirabegron 50mg
Drug: Mirabegron 50mg
Drug: mirabegron 25 mg
Drug: Montelukast 10 mg
Drug: montelukast (5mg QD)
Recruitment Status: Not recruiting
Phase: Phase 4
Date of First Enrollment: July 1, 2024
Target Sample Size: 78
Countries of Recruitment:...